Endeavor BioMedicines’ Post

Could a patient’s gut microbiome influence how they will respond to immunotherapy? Join Rachel Newsome, PhD, from Dr. Christian Jobin's lab at the Univ. of Florida, for a webinar on Feb. 21st featuring the findings from a study of Bacteroides-enhanced gut microbiomes associated with an enhanced response to anti-PD-1 therapy in NSCLC patients. Characterization of live Bacteroides isolates led to the discovery of a novel influential metabolite that stimulates IFNγ in CD8+ T cells, and in combination with anti-PD-1 therapy, significantly reduces tumor growth in a NSCLC mouse model. Save your seat for this informative discussion and learn about the high-throughput isolation and cultivation methods that, not only enabled this discovery, but can empower any microbiome-based product or drug development program. Register here:  https://lnkd.in/g8dJcFYb #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector

Dear CFO of scaleups Dear team of Hemotune AG Funding remains a key issue ! Great Sami (Finance) that Hemotune secures funds. The scaleup ecosystem needs to support longterm development. Overcoming Challenges: Simplify complexities, adapt with flexible scalability, prioritize compliance strategically, and master timing and funding for a seamless scale-up path. Join in shaping scale-up strategies and set up your company for success. https://www.fbxperts.ch 💼🌐 #ScaleUpStrategies #BusinessGrowth #InternationalizationDrivers#

Could a game-changing solution to the treatment of solid tumors and autoimmune diseases be on the horizon? A fascinating new article from UKT news dives into the remarkable possibilities of T-Cypher Bio's D-Cypher, an integrated platform that could potentially revolutionize the biotech industry. This Oxford-based startup are planning to overcome the challenges met with current therapeutics, as they push the boundaries of science to transform lives. Don't miss out on this enlightening read: https://UKT.news/?p=10417 #Biotech #HealthcareInnovation #TCRBiotherapeutics #DCypher #OxfordStartup

🚀 Exciting News! Bastion Therapeutics Secures $840K in Launch Financing 🚀   🏰 We are thrilled to announce a major milestone for Bastion Therapeutics! We've secured $840,000 in launch financing to revolutionise the treatment of #InflammatoryDisorders and #AutoimmuneDiseases with our cutting-edge #Treg cell therapies.   💪 #Tregs play a pivotal role in a healthy immune system, expertly keeping #inflammation in check. In patients suffering from chronic inflammatory and autoimmune conditions, Tregs fail to control the relentless inflammation. 🛡️🔥Our #BastionVanguard is on a quest to not only restore but supercharge the function of Tregs with our GRIT™ Platform Technology, zeroing in on those sites of tissue inflammation.   🤝 This incredible funding round was led by NG Bio, a specialist investor in immunology and inflammatory diseases, along with Pioneer Group, Wren Capital LLP, and Deep Science Ventures.   🔬 We've already generated promising preclinical data, validating our Treg engineering technology. With this financing, we'll build our research capabilities, advance product development, and establish our laboratory at Scale Space.   🙌 Together with NG Bio, Pioneer Group, Wren Capital LLP, Deep Science Ventures, and our brilliant angel investors😇, we're on a mission to provide curative treatments for patients battling inflammatory disorders.   Visit our website to read the full press release 👇 https://lnkd.in/eQEg__xH   #Tregs #BastionTherapeutics #CellTherapy

The first IHI projects kicked off earlier this year and are already making strides! 🏃 Find out more about them: 💉 GUIDE.MRD ➡️ investigating the use of blood tests to determine which cancer patients, post-surgery, will need to undergo additional therapies 🎯 IMAGIO_project ➡️ developing mini-imaging tools that will improve targeting of cancer cells during treatment 🔎 IDERHA ➡️ linking up public and private databases to create a searchable health data platform 👨💻 CLAIMS ➡️ developing a diagnostic platform which will apply AI models to accurately predict responses of patients with MS to various treatments. 👵🏾 IHI-PROMINENT’s digital platform will pave the way for personalised treatment of people with #Alzheimer’sDisease Want to know more? ➡️ https://europa.eu/!Ycqhx4 #IHITransformingHealth #HealthResearch #EUInnovation #MedTech #HealthTech EU Science, Research and Innovation COCIR EFPIA - European Federation of Pharmaceutical Industries and Associations EuropaBio - the European Association for Bioindustries MedTech Europe Vaccines Europe

"The company showed that its oral small molecule GT-02287 was capable of restoring motor function in mouse models of GBA1 Parkinson’s to nearly the levels of healthy controls." Today's #KCRScienceRead highlights a potential breakthrough in #ParkinsonsDisease #research. Current #treatments focus on symptom management, not in slowing or stopping disease progression. In a recent study of Gain Therapeutics’ phase 1 drug, the #treatment appeared to restore motor function in mice - suggesting a potentially disease-modifying therapy. Check it out! https://lnkd.in/eTWznKsZ #KCRCRO #ClinicalTrials #ClinicalResearch #Innovation #Parkinsons

The search for effective treatments for inflammatory bowel disease is driven by advancements in preclinical research employing diverse IBD mouse models. Choosing a mouse model for IBD preclinical studies is not always straightforward but is a prerequisite for reliable outcomes. Join this Tech Talk to gain expert guidance on the advantages and disadvantages of different irritable bowel disease models.

In business news, Endeavor BioMedicines announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument. Endeavor will use the financing proceeds to advance the clinical development of ENV-101, an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway being evaluated as a treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company will also use the funding to advance ENV-501, a human epidermal growth factor 3 (HER3) antibody-drug conjugate for the treatment of HER3-positive solid tumors through clinical proof-of-concept studies. Endeavor intends to initiate a Phase 1/2 trial of ENV-501 in 2024. #mabs #adcs https://lnkd.in/d92pFwUY

The development of successful therapies necessitates the assessment of a drug's effect on multiple cells or tissue types. Modelling these complex interactions is often acheieved at the expense of scalability, thus posing a challenge for drug development. At HUB, we set up unique organoid co-cultures to allow the development of immunomodulatory agents within the tumor microenvironment. Want to discuss how this could help your research? Join us at #AACR2024. Our organoid expert will be happy to assist you in how our proprietary technology can help you move your immunotherapy agent to the clinical trials with confidence. Click in the link below to book a meeting with us --> https://bit.ly/4atqvWf #organoids #AACR2024 #cancerresearch #tumoroids #tumororganoids #patientinalab #oncologytrials #drugdevelopment #cocultures #tumormicroenvironment #immunecells #immunotherapy #immunecheckpointinhibitors #PDL1 #KRAS

Great to be at #bioequity24 supporting and representing MitoRx Therapeutics as we seek investors for our Series A raise. MitoRx Therapeutics is an Oxford based preclinical stage platform biotech developing mitochondrial-targeted small molecules that uniquely restore sulfide-signaling, a conserved system required for adaptive metabolism, recently achieving preclinical platform validation. We have generated positive results in 3 preclinical programs in neuromuscular, obesity and lung inflammatory disease. In a severe fibrotic rodent model of Duchenne MD muscle degeneration is halted and impaired weight gain is reversed, a unique metabolic rescue among muscular dystrophy efforts. In a rodent obesity model, we observed highly significant reduction in weight gain, inflammation and liver injury. In a COPD model with our compounds reduce fibrosis, blunt inflammasome activation and preserve function. MitoRx Therapeutics have raised £5m since 2022, built a team that has taken 5 drugs to market, and filed on five compositions of matter patents. Our approach in highly innovative: first in class, first in mechanism and first in target. We are seeking research collaboration and option deals with pharma and investors who want to back us to the clinic.